This website uses cookies
Read our Privacy policy and Terms of use for more information.
Jun 25, 2026
White House denies Trump received Lilly's experimental GLP-1 retatrutide as AbbVie, Lilly and Evaluate reshape biotech's outlook.
Jun 18, 2026
Novo Nordisk rejects multimillion-dollar ransom demands as biopharma dealmaking surges and uniQure moves closer to a Huntington's approval filing.
Jun 16, 2026
A giant liver lands in Philly, Germany backs away from drug pricing reforms, FDA AI adoption accelerates, and biotech professionals debate when hiring will recover.
Jun 11, 2026
GLP-1s may influence depression through the gut while pharma companies look beyond Earth for innovation.
Jun 9, 2026
Researchers get removed from ADA conference after handing out a funding-cuts editorial, while obesity drug developers steal the spotlight in New Orleans.
Jun 4, 2026
Anti-aging biotech lands $435M, China dominates ASCO, and Lilly keeps writing billion-dollar checks.
Jun 2, 2026
Revolution Medicines earns a standing ovation at ASCO, Pfizer signs a $10B oncology partnership, and Lilly keeps its deal spree alive.
May 28, 2026
The FDA reassembles vaccine advisers, Lilly spends another $3.8B on biotech acquisitions, and Washington debates whether China licensing is becoming a national security risk.
May 26, 2026
Moderna heads back into the FDA arena, Lilly posts bariatric-level weight loss numbers, and biotech may be getting its own betting market.
